Pentagon ordered to map biotech's role in national defense
H.R. 6009 — Defense Biotechnology Strategy Act · Filed by Chrissy Houlahan (D-PA) · 2 cosponsors · Introduced Nov 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Secretary of Defense to develop a comprehensive strategy within one year on how emerging biotechnologies affect U.S. national security, including how the military can develop biotech manufacturing capacity, update procurement standards, enter advance purchase agreements, and coordinate with NATO allies on biotech research and purchasing. The bill creates no new spending, no new agency, and no direct beneficiaries—it is a planning and coordination mandate.
Why we flagged it
The bill is a procedural directive requiring the Department of Defense to study and report on biotechnology strategy. It contains no substantive policy changes, no spending, and no regulatory action—only a requirement to develop and submit a strategic plan to Congress within one year.
What the text implies
- The strategy may recommend advance market commitments (AMCs) and offtake agreements for biotech products, which could commit future defense budgets to purchasing specific biotech products before they are fully developed or proven cost-effective.
- NATO coordination provisions (elements 7–8) could lead to pooled international purchasing agreements that bind U.S. procurement to allied demand, potentially limiting domestic biotech vendor competition.
- The mandate to develop a 'biotechnology regulation science and technology program' and 'digital infrastructure to support simplified regulation' suggests the strategy may recommend streamlined approval pathways for biotech products in defense contexts, which could reduce safety review timelines.
- The strategy's focus on 'commercial facilities for biomanufacture' and 'industry relationships' may recommend subsidies, tax incentives, or preferential procurement for private biotech firms, though the bill itself does not authorize spending.
- Wargaming and net assessment exercises incorporating biotech applications could normalize military use of emerging biotechnologies (e.g., synthetic biology, gene editing) before public debate or regulatory frameworks are in place.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill itself creates no direct public benefit or cost—it is a planning mandate with no spending, no new restrictions on citizens, and no immediate policy changes. However, the strategy it mandates could eventually inform defense procurement and biotech regulation that affects public health, biosecurity, and dual-use research oversight. The outcome depends entirely on what the strategy recommends and whether Congress acts on it.
Who stands to gain
- biotechnology companies (potential future procurement beneficiaries if strategy recommends AMCs or o
- defense contractors with biotech divisions
- commercial biomanufacturing facilities (if strategy recommends government support or preferential co
Named in the bill
Department of Defense, Secretary of Defense, Under Secretary of Defense for Research and Engineering, Under Secretary of Defense for Acquisition and Sustainment, House Committee on Armed Services, Senate Committee on Armed Services, NATO, biotechnology industry
Where it stands
2 cosponsors: 2 Republicans.
- Nov 10, 2025 — Introduced · Congress.gov: “Introduced in House”
- Nov 10, 2025 — Referred to House Committee on Foreign Affairs and House Committee on Armed Services · Congress.gov: “Referred to the Committee on Armed Services, and in addition to the Committee on Foreign Affairs, for a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $732,000 in lobbying spend. A filing names 25 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Chrissy Houlahan, the sponsor, reported $539,500 in PAC receipts in the 2026 cycle.
- Enbridge (u.s.) Inc — $732,000 on 2 filings
Lobbying Disclosure Act filings through Jul 23, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (2,639 characters) on Jun 3, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 23, 2026 · page rendered 2026-10-20.
“Pentagon ordered to map biotech's role in national defense” QuorumCivic. https://share.quorumcivic.app/bill/119/hr6009 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.